Oxford Spin-Out OMass Just Landed $300M—Here's Why Investors Are Betting Big

Jan de Vries · 2026-10-16

OMass Therapeutics, a UK biotech spun out of Oxford, just closed an oversubscribed $300 million Series C round. That's a lot of cash for a company most people have never heard of. But if you follow European biotech, you know this one's been on the radar for a while. The round was co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings. Janus Henderson, SV Health Investors, and Jefferson Life Sciences also joined in. And pretty much every existing investor—Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and the University of Oxford—came back for more. That kind of loyalty tells you something. ### Why OMass Matters OMass isn't your typical biotech. Founded in 2016, it grew out of Professor Dame Carol Robinson's lab at Oxford. The goal? Turn native mass spectrometry research into real drugs for targets that have historically been tough to crack. Their secret sauce is the OdyssION platform. It combines next-gen native mass spectrometry, novel biochemistry, and custom chemistry to study drug targets in their native environments. Think of it as getting cell-system fidelity with cell-free precision. That's a mouthful, but it basically means they can see how drugs interact with targets in a more realistic setting. > "This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow." — Ros Deegan, CEO of OMass Therapeutics ### The Pipeline: OMS1620 and Beyond The lead program, OMS1620, is a potential best-in-class MC2 receptor antagonist. It's heading into Phase 2 trials for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. Those are serious conditions with limited treatment options, so a new approach could be a game-changer. And OMS1620 isn't alone. OMass has been building a pipeline of first- and best-in-class programs in endocrinology and immunology. The company's approach has already shown it can deliver candidates into the clinic. ### A Hot Year for European Biotech OMass' round is part of a bigger trend. European therapeutics startups are raking in cash this year. Just look at these recent rounds: - Bionyra Pharma (France): $155 million for inflammatory diseases - Breye Therapeutics (Denmark): $73 million for oral small-molecule pipeline - STORM Therapeutics (UK): $51 million - Microbiotica (UK): $45 million - Mironid (UK): $43 million - Alchemab Therapeutics (UK): $32 million - Laigo Bio (Netherlands): $6 million Add those up and you get roughly $406 million in new financing. Include OMass and that number jumps to over $700 million. That's a lot of confidence in European biotech. ### What the Investors Are Saying Evan Greif, Principal at Bain Capital Life Sciences, put it this way: "OMass leverages an experienced team and a clear vision for building a leading therapeutics company that translates complex biology into differentiated medicines for patients with significant unmet needs." Max Klement, Partner at Novo Holdings, added: "We are pleased to join a premier investor syndicate supporting OMass as the Company advances its breakthrough programs into the clinic." ### What's Next for OMass? The new funds will push OMS1620 through Phase 2 development. If successful, it could offer a new option for patients with CAH and Cushing's syndrome. The company also plans to advance its SLC15A4 inhibitor and other pipeline programs. For those of us watching the European startup scene, OMass is a name to remember. It's not just about the money—it's about the science. And with this round, OMass has the resources to turn that science into real treatments. So keep an eye on Oxford. The next big thing in biotech might just come from there.